NEUROCRINE BIOSCIENCES INC
NBIX · XNASCIK 914475fmd_1K85FD8PBCFJ9JN11M5330KQYTManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 15 | 162 | 451 | 788 | 1,046 | 1,134 | 1,489 | 1,887 | 2,355 | 2,861 |
| Cost of revenue | 0 | 1 | 5 | – | 10 | 14 | 23 | 40 | 34 | 52 |
| Realized investment gains (losses) | 0 | – | – | – | – | – | – | – | – | – |
| Gross profit | 15 | 160 | 446 | – | 1,036 | 1,119 | 1,466 | 1,847 | 2,321 | 2,808 |
| Research and development | 94 | 122 | 161 | – | 275 | 328 | 464 | 565 | 731 | 1,016 |
| Selling, general and administrative | 68 | 170 | 249 | 354 | 433 | 583 | 753 | 888 | 1,007 | 1,156 |
| Total operating expenses | 162 | 293 | 414 | 716 | 883 | 1,031 | – | – | – | – |
| Operating income | (147) | (131) | 37 | 72 | 163 | 103 | 249 | 251 | 571 | 619 |
| Interest expense | 0 | 20 | 31 | 32 | 33 | 26 | 7 | 5 | – | – |
| Interest and investment income | 3 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 6 | (11) | (15) | (26) | (56) | (1) | (35) | 81 | (85) | 86 |
| Income before taxes | (141) | (143) | 22 | 47 | 107 | 101 | 214 | 332 | 486 | 705 |
| Income tax expense | 0 | 0 | 1 | 10 | (301) | 12 | 59 | 82 | 145 | 227 |
| Net income from continuing operations | (141) | (143) | 21 | 37 | 407 | 90 | 155 | 250 | 341 | 479 |
| Net income | (141) | (143) | 21 | 37 | 407 | 90 | 155 | 250 | 341 | 479 |
| Net income to common shareholders | – | – | – | – | 407 | 90 | 155 | 250 | 341 | 479 |